From an open label randomized controlled trial, Castillo et al. (2020) report the effect of Calcifediol (Vitamin D) as an adjunct therapeutic intervention on ICU admission among patients hospitalized for COVID-19. To quote the paper: "Univariate Risk Estimate Odds Ratio for ICU in patients with Calcifediol treatment versus without Calcifediol treatment: 0.02 (95 %CI 0.0020.17)." Source: Castillo et al. (2020). Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study. J Steroid Biochem Mol Biol. doi: 10.1016/j.jsbmb.2020.105751. These results suggest that Calcifediol as an adjunct therapeutic intervention